The U.K. Patents Court has held Warner-Lambert’s second medical use patent regarding the use of pregabalin for the treatment of pain invalid on the ground of insufficiency. Even if the patent were valid, the Court held that Actavis would not have infringed Warner-Lambert’s patent as a result of any “cross-label” use of their product sold on a skinny label.

A full summary of this case has been published on Kluwer IP Law.


_____________________________

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.


Kluwer IP Law
image_pdfimage_print